A major revision to the antibiotics section includes the categorization of these agents into three groups: ACCESS, WATCH, and RESERVE.
The use of fluoroquinolones in patients with respiratory infections was found to delay the diagnosis of active pulmonary tuberculosis, according to a study presented at IDWeek 2016.
The 2016 Treatment of Drug-Susceptible Tuberculosis Guidelines have been released as an update to the previous tuberculosis (TB) guidelines published in 2003.
Patients hospitalized for serious infections may face an increased risk of suicide, according to research published online in JAMA Psychiatry.
The U.S. Preventive Services Task Force (USPSTF) recommends screening for latent tuberculosis infection (LTBI) in adults at increased risk.
Babies exposed to chemicals such as PCBs and DDT show weakened responses to the tuberculosis vaccine, according to a new study.
Sanofi announced the launch of new 24- and 32-packs of Priftin (rifapentine) for the treatment of patients with latent and active tuberculosis (TB).
Patients with rheumatoid arthritis (RA) who initiate TNF inhibitor therapy have an increased risk of tuberculosis, with the highest risk of incidence within the first 6 months, researchers concluded at the 2015 ACR/ARHP Annual Meeting.
Patients with HIV and tuberculosis (TB) coinfection are discontinuing first-line antitubercular therapy (ATT) at disturbingly high rates because of side effects like skin reactions, gastrointestinal symptoms, and hepatotoxicity, according to study findings reported at IDWeek 2015.
Initiating antitretroviral therapy (ART) within two weeks of tuberculosis (TB) diagnosis improved survival among patients with HIV, TB, and moderately to severely compromised immune systems in research published in the Annals of Internal Medicine.
Fluoroquinolone therapy for contacts of individuals with multi-drug resistant tuberculosis is associated with cost savings and reduced incidence of multi-drug resistant tuberculosis, according to a study published in the American Journal of Respiratory and Critical Care Medicine.
The National Institutes of Health (NIH) has confirmed that while a woman with a rare form of tuberculosis (TB) is currently undergoing treatment, she may have exposed hundreds of people to this treatment-resistant infection.
A pathogen can develop resistance faster in a "pocket" of the body where only one drug is present compared to where no pockets exist, a new study published in the Proceedings of the National Academy of Sciences has shown.
The National Institutes of Health (NIH) has issued a statement for World TB Day on the need to effectively diagnose, treat, and cure those infected with tuberculosis (TB).
More than 300 students and staff at Olathe Northwest High School in Kansas were tested last week after a reported case of tuberculosis (TB) at the school.
Implementation of a culture-based screening algorithm in 2007 reduced the incidence of tuberculosis (TB) among immigrants and refugees bound for the United States, according to a new study.
In 26 U.S. tuberculosis outbreaks the initial source case-patients had long incubation periods and were characterized by substance abuse, incarceration, and homelessness.
The Food and Drug Administration (FDA) has granted clearance for the Cepheid Xpert MTB/RIF Assay to help determine if patients with suspected tuberculosis (TB) can be removed from airborne infection isolation with one or two negative test results.
Sanofi announced that the FDA has approved Priftin (rifapentine) in combination with isoniazid for the treatment of latent tuberculosis infection in patients aged ≥2 years at high risk of progression to tuberculosis disease.
In a new study using the FDA Adverse Event Reporting System database, researchers sought to determine clinically meaningful adverse events reported for 15 relatively new amtimicrobial agents.
New policy guidelines issued by the White House Office of Science and Technology Policy are calling for U.S. universities to carefully monitor their life sciences research on dangerous pathogens and toxins for both benefits and risks.
For patients with uncomplicated, smear-positive pulmonary tuberculosis, moxifloxacin-containing regimens over four months are not noninferior to a control regimen.
After an extensive review by the CDC's internal Laboratory Safety Improvement Working Group, CDC Director Tom Frieden, MD, MPH, has lifted the moratorium on a specific type of material transfer for the CDC's Clinical Tuberculosis Laboratory.